Beta-Adrenergic Modulation of Drug Cue Reactivity

Recruiting Phase 4 Interventional Study
Tobacco Use Disorder Nicotine Dependence Cigarette Smoking
Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 – 60
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Basic Science
Participants needed
80 (estimated)
Sponsor
University of Oklahoma · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation at…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Generally healthy 2. Age 21-60 3. Right-handed using a three-item scale 4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC) 5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months 6. Afternoon expired Carbon Monoxide (CO) concentration …
Contacts

Jason A Oliver, PhD

405-271-8001

Jason-Oliver@ouhsc.edu

CONTACT

Isabel Brush, B.A.

Isabel-Brush@ouhsc.edu

CONTACT